EP4543409A1

EP4543409A1 - Stabilization of thiopyridinone compound and composition comprising same

Info

Publication number: EP4543409A1
Application number: EP23738926.7A
Authority: EP
Inventors: Makoto Saito; Romain TACHON; Noemie Bromberger; Yuan Luo; Jun Suzuki; Xiaomin Weng; Ning Chang; Huiqin Chen
Original assignee: LOreal SA
Current assignee: LOreal SA
Priority date: 2022-06-21
Filing date: 2023-06-16
Publication date: 2025-04-30
Also published as: WO2023249122A1

Abstract

The present invention relates to a composition comprising: (1) at least one thiopyridinone compound; and (2) at least one lipophilic antioxidant, or (2') a combination of (i) at least one antioxidant selected from cinnamic acid or a derivative thereof, hindered phenols or semi- hindered phenols, and thioester antioxidant; e.g., pentaerythrityl tetra-di-t-butyl hydroxyhydrocinnamate, tris(tetramethylhydroxypiperidinol) citrate; and (ii) at least one chelating agent selected from the group consisting of succinic acid and derivatives thereof, phosphor-containing organic acid and derivatives thereof. The present invention can provide a composition including (1) thiopyridinone compound(s) with increased stability of the (1) thiopyridinone compound(s) over time, in particular even when the composition is maintained for a relatively long period of time under elevated temperature.

Description

DESCRIPTION

TITLE OF INVENTION

STABILIZATION OF THIOP YRIDIN ONE COMPOUND AND COMPOSITION COMPRISING SAME

TECHNICAL FIELD

The present invention relates to the stabilization of a thiopyridinone compound in a composition including the thiopyridinone compound.

BACKGROUND ART

At various periods of their lives, some people see the appearance on their skin, and more in particular on their faces and hands, of darker and/or more colored spots, which give the skin heterogeneity. These spots are in particular due to a high concentration of melanin in the keratinocytes located at the surface of the skin.

The use of harmless topical depigmenting substances with good efficacy is most particularly desired for the purpose of treating pigmentation spots.

For example, arbutin, niacinamide and kojic acid are known as skin depigmenting agents.

On the other hand, WO2017/102349 discloses a new depigmenting or whitening agent, i.e., a thiopyridinone compound. The thiopyridinone compound can show strong depigmenting or whitening effects by reducing the production of melanin.

DISCLOSURE OF INVENTION

However, it has been discovered that a thiopyridinone compound tends to be destabilized in a composition over time, in particular when the composition including the thiopyridinone compound is maintained for a relatively long period of time under elevated temperature.

Thus, an objective of the present invention is to provide a composition including thiopyridinone compound(s) with increased stability of the thiopyridinone compound(s) over time, in particular when the composition is maintained for a relatively long period of time under elevated temperature.

The above objective can be achieved by a composition comprising:

(1) at least one compound selected from compounds of formula (I) below, tautomers of formula (I’) below, salts thereof, solvates, such as hydrates, thereof, optical isomers thereof, racemates thereof, and mixtures thereof: (I) (D in which

Ri denotes a radical chosen from a) a hydrogen atom, and b) a saturated, linear C1-C10 or branched C3-C10 alkyl group optionally substituted with one or more groups, which may be identical or different, chosen from i) -O-R3, and ii) -S-R3, and

R2 denotes a radical chosen from a) a hydrogen atom, b) a saturated, linear C1-C12 or branched C3-C12 or cyclic C3-C8 hydrocarbonated group optionally substituted with one or more groups, which may be identical or different, chosen from i) -O-R3, ii) -S-R3, iii) -C(O)-O-R₃, and iv) a C5-C12 aryl group optionally substituted with one or more hydroxyls and/or with one or more Ci-Cs alkoxy radicals, and c) a C5-C12 aryl group optionally substituted with one or more hydroxyls and/or with one or more Ci-C« alkoxy radicals, wherein

R3 denotes a radical chosen from a) a hydrogen atom, and b) a saturated, linear C1-C10 or branched C3-C10 alkyl group; and

(2) at least one lipophilic antioxidant; or

(2’) a combination of:

(i) at least one antioxidant selected from cinnamic acid or a derivative thereof, hindered phenols or semi-hindered phenols, and thioester antioxidant; e.g., pentaerythrityl tetra-di-t-butyl hydroxyhydrocinnamate, tris(tetramethylhydroxypiperidinol) citrate; and

(ii) at least one chelating agent selected from the group consisting of succinic acid and derivatives thereof, phosphor-containing organic acid and derivatives thereof.

It may be preferable that:

Ri of formula (I) and (I’) represents a hydrogen atom; or

Ri of formula (I) and (!’) represents a linear (C1-C10) alkyl group or a branched (C3-C10) alkyl group, especially a linear (Ci-Ce) alkyl group or a branched (C3-C6) alkyl group, such as methyl, ethyl, n-pentyl, n-nonyl, isobutyl, more preferably ethyl, particularly the said alkyl group of Ri is not substituted.

It may be preferable that:

R2 of formula (I) and (I’) represents a hydrogen atom; or

R2 of formula (I) and (I’) represents a linear (C1-C10) alkyl group or a branched (C3-C10) alkyl group, especially a linear (Ci-Ce) alkyl group or a branched (C3-C6) alkyl group, such as methyl, ethyl, n-pentyl, n-nonyl, isobutyl, more preferably methyl or ethyl group; the said alkyl group of R2 being not substituted.

It may be preferable that:

R2 of formula (I) and (I’) represents a linear (C1-C10) alkyl group or a branched (C3-C10) alkyl group, especially a linear (Ci-Ce) alkyl group or a branched (C3-C6) alkyl group, such as methyl, ethyl, n-pentyl, n-nonyl, isobutyl, more preferably methyl or ethyl; the said alkyl group being substituted by one or more groups selected from i), ii), iii) and iv) as defined above, preferably the said alkyl group being substituted by one or two groups selected from i), ii) and iii), more preferably by one or two groups selected from i) and iii), better substituted by one group iii) as carboxy.

It may be preferable that:

R2 of formula (I) and (I’) represents a (C3-C8) cycloalkyl group, preferably a (C5-C7) cycloalkyl group such cyclohexyl; or

R2 of formula (I) and (I’) represents a C5-C12 aryl group optionally substituted with one or more hydroxyls and/or with one or more Ci-Cs alkoxy radicals, preferably a phenyl group particularly not substituted.

It may be preferable that:

R3 of formula (I) and (I’) represents a hydrogen atom; or

R3 of formula (I) and (I’) represents a saturated, linear C1-C10 or branched C3-C10 alkyl group; particularly a linear (Ci-Ce) alkyl group or a branched (C3-C6) alkyl group, preferably a (Ci- C4) alkyl group such as methyl group.

It may be more preferable that:

Ri of formula (I) and (I’) represents a radical chosen from a) a hydrogen atom, and b) a saturated, linear Ci-Ce or branched C3-C6 alkyl group optionally substituted with one or more groups, which may be identical or different, chosen from i) -O-R3, and ii) -S-R₃, preferably optionally substituted with one or more groups i);

R2 of formula (I) and (I’) represents a radical chosen from a) a hydrogen atom, and b) a saturated, linear C1-C10 or branched C3-C10 or cyclic C3-C8 such as C5-C6 hydrocarbonated group, optionally substituted with one or more groups, which may be identical or different, chosen from i) -O-R3, ii) -S-R3, iii) -C(O)-O-R3, and iv) a phenyl group optionally substituted with one or more hydroxyls and/or with one or more C1-C4 alkoxy radicals such as methoxy, preferably substituted with one or more groups selected from i) and iii), preferably iii) such as carboxy; and

R3 of formula (I) and (I’) represents a radical chosen from a) a hydrogen atom, and b) a saturated, linear Ci-Ce or branched C3-C6 alkyl group, preferentially, the compounds of formula (I) and tautomer (I’), salts thereof, solvates, such as hydrates, thereof, optical isomers thereof, racemates thereof, and mixtures thereof, have the following meanings:

Ri of formula (I) and (I’) represents a radical chosen from: a) a hydrogen atom, and b) a saturated, linear C1-C4 or branched C3-C4 alkyl group optionally substituted with one or more groups, which may be identical or different, chosen from i) -OR3 , more preferably not substituted;

R2 of formula (I) and (I’) represents a radical chosen from a) a hydrogen atom, and b) a saturated, linear C1-C10 or branched C3-C10 or cyclic C3-C8 such as C5-C6 hydrocarbonated group, optionally substituted with one or more groups, which may be identical or different, chosen from i) -O-R3, iii) -C(O)-O-R₃, and iv) a C5-C12 aryl group optionally substituted with one or more hydroxyls and/or with one or more C1-C4 alkoxy radicals; and

R3 of formula (I) and (I’) represents a radical chosen from: a) a hydrogen atom; b) a saturated, linear C1-C4 or branched C3-C4 alkyl group such as methyl or ethyl.

The (1) compound may be selected from the compounds 1 to 24 below, tautomers thereof, salts thereof, solvates, such as hydrates, thereof, optical isomers thereof, racemates thereof, and mixtures thereof, particularly the compounds 1, 2, 4, 6, 7, 9, 11, 12, 14, 15, 16, 17, 18, 19, 20, or 21, more particularly 1, 9, 16, 18, 19, 20, or 21, preferably 18, 19, 20, or 21, and more preferably 20:

SUBSTITUTE SHEETfRULM

SUBST1W SHEETffilW®

SUBSTITUTE SHEET(RlM

The amount of the (1) compound(s) in the composition according to the present invention may be from 0.01% to 10% by weight, preferably from 0.05% to 5% by weight, and more preferably from 0.1% to 3% by weight, relative to the total weight of the composition.

The (2) lipophilic antioxidant may be selected from the group consisting of dibutylhydroxytoluene, ethylhexyl methoxycrylene, tocopheryl acetate, oryzanol, pentaerythrityl tetra-di-t-butyl hydroxyhydrocinnamate, dilauryl thiopropionate, and mixtures thereof.

The amount of the (2) lipophilic antioxidant(s) in the composition according to the present invention may be from 0.01% to 10% by weight, preferably from 0.05% to 5% by weight, more preferably from 0.1% to 3% by weight, relative to the total weight of the composition.

The (2’) (ii) chelating agent may be selected from ethylenediamine disuccinic acid (EDDS), and a salt thereof; phosphor-containing organic acid, e.g., phytic acid, and a salt thereof, e.g., sodium phytate, potassium phytate.

The (2’) combination may further comprise (2’) (iii) at least one antioxidant selected from the group consisting of tetrahexyl decyl ascorbate/erythorbate and ascorbyl palmitate, ascorbyl dipalmitate, ascorbyl tetraisopalmitate, magnesium ascorbyl phosphate, ascorbyl glucoside, glucosamine ascorbate, ascorbyl acetate, and tris(tetramethylhydroxypiperidinol) citrate.

The amount of the (2’) (i) antioxidant(s) in the composition according to the present invention may be from 0.1% to 2% by weight, preferably from 0.1% to 1% by weight, more preferably from 0.1% to 0.5% by weight, relative to the total weight of the composition; and/or the amount of the (2’) (ii) chelating agent(s) in the composition according to the present invention is from 0.001% to 1% by weight, preferably from 0.01% to 0.5% by weight, relative to the total weight of the composition; and/or the amount of the (2’) (iii) antioxidant(s) in the composition according to the present invention is from 0% to 2% by weight, preferably 0.1% to 1% by weight, more preferably 0.1% to 0.5% by weight, relative to the total weight of the composition. Another aspect of the present invention is a use of:

(2) at least one lipophilic antioxidant; or

(2’) a combination of:

(ii) at least one chelating agent selected from the group consisting of succinic acid and derivatives thereof, phosphor-containing organic acid and derivatives thereof, in a composition comprising (1) at least one compound selected from compounds of formula (I) below, tautomers of formula (I’) below, salts thereof, solvates, such as hydrates, thereof, optical isomers thereof, racemates thereof, and mixtures thereof: in which

Ri denotes a radical chosen from a) a hydrogen atom, and b) a saturated, linear Ci-Cio or branched C3-C10 alkyl group optionally substituted with one or more groups, which may be identical or different, chosen from i) -O-R3, and ii) -S-R3, and

R2 denotes a radical chosen from a) a hydrogen atom, b) a saturated, linear C1-C12 or branched C3-C12 or cyclic C3-C8 hydrocarbonated group optionally substituted with one or more groups, which may be identical or different, chosen from i) -O-R3, ii) -S-R3, iii) -C(O)-O-R3, and iv) a C5-C12 aryl group optionally substituted with one or more hydroxyls and/or with one or more Ci-Cs alkoxy radicals, and c) a C5-C12 aryl group optionally substituted with one or more hydroxyls and/or with one or more Ci-Cs alkoxy radicals wherein

R3 denotes a radical chosen from a) a hydrogen atom, and b) a saturated, linear C1-C10 or branched C3-C10 alkyl group in order to stabilize the (1) compound(s).

BEST MODE FOR CARRYING OUT THE INVENTION After diligent research, the inventors have discovered that it is possible to provide a composition including a thiopyridinone compound or thiopyridinone compounds with increased stability of the thiopyridinone compound(s) over time, in particular even when the composition is maintained for a relatively long period of time under elevated temperature.

Thus, the composition according to the present invention comprises:

(1) at least one compound selected from compounds of formula (I) below, tautomers of formula (I’) below, salts thereof, solvates, such as hydrates, thereof, optical isomers thereof, racemates thereof, and mixtures thereof (hereafter, the compound is referred to as “thiopyridinone compound”): in which

R2 denotes a radical chosen from a) a hydrogen atom, b) a saturated, linear C1-C12 or branched C3-C12 or cyclic C3-C8 hydrocarbonated group optionally substituted with one or more groups, which may be identical or different, chosen from i) -O-R3, ii) -S-R3, iii) -C(O)-O-R₃, and iv) a C5-C12 aryl group optionally substituted with one or more hydroxyls and/or with one or more Ci-Cs alkoxy radicals, and c) a C5-C12 aryl group optionally substituted with one or more hydroxyls and/or with one or more Ci-Cg alkoxy radicals, wherein

(2) at least one lipophilic antioxidant; or

(2’) a combination of:

The composition according to the present invention can show increased stability of the (1) thiopyridinone compound therein.

In other words, the composition according to the present invention can increase the stability of the (1) thiopyridinone compound therein. The term “stability” of the (1) thiopyridinone compound can be determined by the change in the amount of the (1) thiopyridinone compound in the composition according to the present invention during a certain period of time. An increased “stability” means that the change in the amount of the (1) thiopyridinone compound over time is. more limited.

The composition according to the present invention can show increased stability of the (1) thiopyridinone compound therein, even when the composition is maintained for a relatively long period of time such as two weeks under elevated temperature such as 55°C.

Therefore, the composition according to the present invention can be stored for a long period of time even under hot conditions.

In addition, the increased stability of the (1) thiopyridinone compound can provide improved or enhanced bioavailability of the (1) thiopyridinone compound which can function as a depigmenting or whitening agent. Therefore, the composition according to the present invention can provide enhanced or improved depigmenting or whitening effects.

Hereafter, the composition, use and the like according to the present invention will be described in a detailed manner.

[Composition]

The composition according to the present invention comprises:

(1) at least one thiopyridinone compound; and

(2) at least one lipophilic antioxidant; or

(2’) a combination of:

The (1) thiopyridinone compound, the (2) lipophilic antioxidant, the (2’) (i) antioxidant, and the (2’) (ii) chelating agent, as well as the other features of the composition according to the present invention will be explained below.

(Thiopyridinone Compound)

The composition according to the present invention comprises (1) at least one thiopyridinone compound. Two or more (1) thiopyridinone compounds may be used in combination.

Thus, a single type of (1) thiopyridinone compound or a combination of different types of (1) thiopyridinone compounds may be used.

The (1) thiopyridinone compound is selected from compounds of formula (I) below, tautomers of formula (I’) below, salts thereof, solvates, such as hydrates, thereof, optical isomers thereof, racemates thereof, and mixtures thereof: in which

R2 denotes a radical chosen from a) a hydrogen atom, b) a saturated, linear C1-C12 or branched C3-C12 or cyclic C3-C8 hydrocarbonated group optionally substituted with one or more groups, which may be identical or different, chosen from i) -O-R3, ii) -S-R3, iii) -C(O)-O-R3, and iv) a C5-C12 aryl group optionally substituted with one or more hydroxyls and/or with one or more Ci-Cs alkoxy radicals, and c) a C5-C12 aryl group optionally substituted with one or more hydroxyls and/or with one or more Ci-Cs alkoxy radicals, wherein

R3 denotes a radical chosen from a) a hydrogen atom, and b) a saturated, linear C1-C10 or branched C3-C10 alkyl group.

Hereafter, for the purposes of the present invention and unless otherwise indicated: a “saturated, linear C1-C12 or branched C3-C12” hydrocarbonated group is equivalent to a “linear (C1-C12) alkyl or branched (C3-C12) alkyl group” which corresponds to a saturated, linear C1-C12 or branched C3-C12 hydrocarbon-based group, preferably a linear C1-C10 or branched C3-C10 hydrocarbon-based group, and more preferably a linear Ci-Ce or branched C3-C6 hydrocarbon-based group; Preferentially, the linear or branched groups may be chosen from methyl, ethyl, propyl, isopropyl, butyl, isobutyl and tert-butyl, pentyl, hexyl, heptyl, octyl, nonyl and decyl; More preferentially, the saturated linear or branched alkyl groups may be chosen from methyl, ethyl, propyl, isopropyl, butyl, isobutyl and tert-butyl, pentyl, hexyl, heptyl and octyl, such as methyl, ethyl, n-pentyl, n-nonyl, isobutyl; a saturated “cyclic C3-C8” hydrocarbonated group is a mono or bicyclic cycloalkyl group containing from 3 to 8 carbon atoms, and especially is a monocyclic cycloalkyl group in C5 to C7 such as a cyclohexyl group, an “alkoxy radical” is an alkyl-oxy radical for which the alkyl radical is a linear or branched C1-C16, and preferentially a Ci-Cs hydrocarbon-based radical; when the alkoxy group is optionally substituted, this implies that the alkyl group is optionally substituted as defined above; an “aryl” group represents a fused or non-fused monocyclic or bicyclic carbon-based group comprising from 5 to 12 carbon atoms, preferably from 6 to 10 carbon atoms, and in which at least one ring is aromatic; preferentially, the aryl radical is a phenyl, biphenyl, naphthyl, more preferably a phenyl group; the term “at least one” is equivalent to the term “one or more”; and the term "inclusive" for a range of concentrations means that the limits of that range are included in the defined range.

The salts of the compounds of formula (I), (I’), (II), or (II’) as defined below comprise the conventional non-toxic salts of said compounds, such as those formed from organic or inorganic acid or from organic or inorganic base.

As salts of the compounds of formula (I), (I’), (II), or (IT), mention may be made of: the salts obtained by addition of the compound of formula (I) or (II) to: a mineral base, such as sodium hydroxide, potassium hydroxide, calcium hydroxide, ammonium hydroxide, magnesium hydroxide, lithium hydroxide, and sodium, potassium or calcium carbonate or hydrogen carbonate for example; or an organic base such as a primary, secondary or tertiary alkylamine, for example triethylamine or butylamine. This primary, secondary or tertiary alkylamine may comprise one or more nitrogen and/or oxygen atoms and may thus comprise, for example, one or more alcohol functions. Mention may be made in particular of 2- amino-2-methylpropanol, ethanolamine, triethanolamine, 2-dimethylaminopropanol, 2-amino-2-(hydroxymethyl)-l ,3 -propanediol and 3-(dimethylamino)propylamine.

Mention may also be made of the salts of amino acids, for instance lysine, arginine, guanidine, glutamic acid and aspartic acid. Advantageously, the salts of the compounds of formula (I) or (II) (when it comprises a carboxy group) may be chosen from alkali metal or alkaline-earth metal salts such as sodium, potassium, calcium or magnesium salts and ammonium salts.

As “organic or inorganic acid salt” is more particularly chosen from salts chosen from a salt derived from i) hydrochloric acid HC1, ii) hydrobromic acid HBr, iii) sulfuric acid H2SO4, iv) alkylsulfonic acids: Alk-S(O)2OH such as methanesulfonic acid and ethanesulfonic acid; v) arylsulfonic acids: Ar-S(O)2OH such as benzenesulfonic acid and toluenesulfonic acid; vi) citric acid; vii) succinic acid; viii) tartaric acid; ix) lactic acid; x) alkoxysulfinic acids: Alk-O- S(O)OH such as methoxysulfinic acid and ethoxysulfinic acid; xi) aryloxysulfinic acids such as tolueneoxysulfinic acid and phenoxysulfinic acid; xii) phosphoric acid H3PO4; xiii) acetic acid CH3C(O)OH; xiv) triflic acid CF3SO3H; and xv) tetrafluoroboric acid HBF4.

The acceptable solvates of the compounds described in the specification comprise conventional solvates such as those formed during the preparation of said compounds owing to the presence of solvents. Mention may be made, by way of example, of the solvates due to the presence of water or of linear or branched alcohols, such as ethanol or isopropanol.

The optical isomers are in particular, the enantiomers and the diastereoisomers.

Compound (I’) is the tautomer form of compound (I) when a tautomeric equilibrium exists according to the following scheme:

According to one embodiment of the present invention, Ri represents one hydrogen atom.

According to another embodiment of the present invention, Ri represents a linear (C1-C10) alkyl group or a branched (C3-C10) alkyl group, especially a linear (Ci-Ce) alkyl group or a branched (C3-C6) alkyl group, such as methyl, ethyl, n-pentyl, n-nonyl, isobutyl, more preferably ethyl. Particularly the said alkyl group of Ri is not substituted.

According to one embodiment of the present invention, R2 represents one hydrogen atom.

According to another embodiment of the present invention, R2 represents a linear (C1-C10) alkyl group or a branched (C3-C10) alkyl group, especially a linear (Ci-Ce) alkyl group or a branched (C3-C6) alkyl group, such as methyl, ethyl, n-pentyl, n-nonyl, isobutyl, more preferably methyl or ethyl group; the said alkyl group of R2 being not substituted.

According to another embodiment of the present invention, R2 represents a linear (C1-C10) alkyl group or a branched (C3-C10) alkyl group, especially a linear (C1-C&) alkyl group or a branched (C3-C6) alkyl group, such as methyl, ethyl, n-pentyl, n-nonyl, isobutyl, more preferably methyl or ethyl; the said alkyl group being substituted by one or more groups selected from i), ii), iii) and iv) as defined above. Preferably the said alkyl group being substituted by one or two groups selected from i), ii), and iii), more preferably by one or two groups selected from i) and iii), better substituted by one group iii) as carboxy.

Another variant for radical R2 is that the said alkyl group is substituted by one group iv) especially substituted by one phenyl group.

According to another embodiment of the present invention, R2 represents a (C3-C8) cycloalkyl group, preferably a (C5-C7) cycloalkyl group such cyclohexyl.

According to another embodiment of the present invention, R2 represents a C5-C12 aryl group optionally substituted with one or more hydroxyls and/or with one or more Ci-Cs alkoxy radicals, preferably a phenyl group particularly not substituted.

According to an embodiment, R3 represents a hydrogen atom. According to another embodiment, R3 represents a saturated, linear Ci-Cio or branched C3-C10 alkyl group; particularly a linear (Ci-Ce) alkyl group or a branched (C3-C6) alkyl group, preferably (C1-C4) alkyl group such as methyl group.

Preferably, the compounds of formula (I) and tautomer (F) or their salts, their optical isomers, racemates, and/or solvates such as hydrates and the thereof, alone or as a mixture have the following meanings:

Ri denotes a radical chosen from a) a hydrogen atom, and b) a saturated, linear Ci-Ce or branched C3-C6 alkyl group optionally substituted with one or more groups, which may be identical or different, chosen from i) -O-R3, and ii) -S-R3, preferably optionally substituted with one or more groups i);

R2 denotes a radical chosen from a) a hydrogen atom; b) a saturated, linear C1-C10 or branched C3-C10 or cyclic C3-C8 such as C5-C6 hydrocarbonated group optionally substituted with one or more groups, which may be identical or different, chosen from: i) -O-R3, ii) -S-R3, iii) -C(O)-O-R₃, and iv) a phenyl group optionally substituted with one or more hydroxyls and/or with one or more C1-C4 alkoxy radicals such as methoxy, preferably substituted with one or more groups selected from i) and iii), preferably iii) such as carboxy; and

R3 denotes a radical chosen from a) a hydrogen atom, and b) a saturated, linear Ci-Ce or branched C3-C6 alkyl group.

Preferentially, the compounds of formula (I) and tautomer (I’) or their salts, their optical isomers, racemates, and/or solvates such as hydrates and the thereof, alone or as a mixture have the following meanings:

Ri denotes a radical chosen from a) a hydrogen atom, and b) a saturated, linear C1-C4 or branched C3-C4 alkyl group optionally substituted with one or more groups, which may be identical or different, chosen from i) -OR3 , more preferably not substituted;

R2 denotes a radical chosen from a) a hydrogen atom; and b) a saturated, linear C1-C10 or branched C3-C10 or cyclic C3-C8 such as C5-C6 hydrocarbonated group, optionally substituted with one or more groups, which may be identical or different, chosen from i) -O-R3, iii) -C(O)-O-R₃, iv) a C5-C12 aryl group optionally substituted with one or more hydroxyls and/or with one or more C1-C4 alkoxy radicals; and

R3 denotes a radical chosen from a) a hydrogen atom, and b) a saturated linear C1-C4 or branched C3-C4 alkyl group such as methyl or ethyl.

Ri is a hydrogen atom; and

R2 denotes a radical chosen from a) a hydrogen atom, and b) a saturated, linear C1-C5 or branched C3-C5 or cyclic C3-C8 such as C5-C6 hydrocarbonated group, substituted with one or more groups, which may be identical or different, chosen from v) -C(O)-O-R3, preferably substituted with one group iii) - C(O)-O-R3; R2 is even more preferably a saturated, linear C1-C4 or branched C3-C4 hydrocarbonated group substituted with one group iii) -C(O)-OR3; and

According to another preferred embodiment, compounds of formula (I) and tautomer (I’) are selected among the compounds of formula (II) below and also the tautomers thereof of formula (II’) below, the salts thereof, the solvates thereof and the optical isomers thereof, and the racemates thereof, alone or as a mixture:

In formula (II) and (II’), Ri and R3 have the same meaning as Ri and R3 in the for compounds of formula (I) and (I’), and X denotes an alkylene radical -(CH2)_n- with n being an integer ranging inclusively from 1 to 10, preferably ranging from 1 to 6, more preferably ranging from 1 to 4, such as 1 , preferably R3 represents a hydrogen atom.

Among the compounds of formula (I), the following compounds are preferably used and their tautomer or their salts, their optical isomers, racemates, and/or solvates such as hydrates and the thereof, alone or as a mixture:

SUBSTITUTE SHEETtUIfiS)

SUBSTITUTE SHEET(RULBS)

Among these compounds, the following compounds are more particularly preferred:

SUBSTITUTE SHEET(RULW)

More preferably, among these compounds, the following compounds are more particularly preferred:

Even more preferably, Among these compounds, the following compounds are more particularly preferred:

In the most preferred embodiment, the compound according to the present invention is the following:

All the compounds above can be obtained by a chemical method known by a person skilled in the art, from commercially available reagents.

The (1) thiopyridinone compound can be prepared in accordance with the process described in, for example, EP-A-3390363 or WO 2017/102349, which is herein incorporated by reference. The (1) thiopyridinone compound may be an active ingredient or active compound in cosmetics or dermatological products. The term “active” ingredient or compound used herein means an ingredient or compound which has a cosmetic or dermatological active property, such as anti-oxidant, whitening, UV-filtering effects and anti-bacterial effects. The (1) thiopyridinone compound used in the present invention can function as a depigmenting, bleaching or whitening agent, and thus the composition according to the present invention may be used as a whitening product or as a cosmetic composition for a whitening keratin substance.

The (1) thiopyridinone compound may be used as an agent for depigmenting, bleaching or whitening the skin, body hairs, the eyelashes or head hair, and also the lips and/or the nails, and preferably the skin, in particular for eliminating pigmentation spots or senescence spots, and/or as an anti-tanning agent.

The amount of the (1) thiopyridinone compound(s) in the composition according to the present invention may be 0.01% by weight or more, preferably 0.05% by weight or more, and more preferably 0.1% by weight or more, relative to the total weight of the composition.

On the other hand, the amount of the (1) thiopyridinone compound(s) in the composition according to the present invention may be 10% by weight or less, preferably 5% by weight or less, and more preferably 3% by weight or less, relative to the total weight of the composition.

The amount of the (1) thiopyridinone compound(s) in the composition according to the present invention may range from 0.01% to 10% by weight, preferably from 0.05% to 5% by weight, more preferably from 0.1% to 3% by weight, relative to the total weight of the composition.

According to another embodiment of the present invention, the amount of the (1) thiopyridinone compound(s) in the composition according to the present invention may range from 0.01% to 10% by weight, preferably from 0.1% to 5% by weight, in particular from 0.5% to 3% by weight, relative to the total weight of the composition.

((2) Lipophilic Antioxidant)

According to one embodiment of the present invention, the composition according to the present invention may comprise (2) at least one lipophilic antioxidant. Two or more lipophilic antioxidants may be used in combination. Thus, a single type of lipophilic antioxidant or a combination of different types of lipophilic antioxidant may be used.

According to the present invention, antioxidants are compounds that can suppress or reduce oxidation. The antioxidants may capture or remove active oxygen species such as singlet oxygen, hydroxyl radical, superoxide anion radical, hydrogen peroxide.

The antioxidants may scavenge the various radical forms which may be present in the skin.

The (2) lipophilic antioxidant is different from the (1) thiopyridinone compound.

A reducing agent may be used as the (2) lipophilic antioxidant.

The (2) lipophilic antioxidant means here that the partition coefficient of the antioxidant between n-butanol and water is >1, more preferably >10 and even more preferably >100.

The (2) lipophilic antioxidant agent is hydrophobic, and is not a hydrophilic antioxidant agent such as ascorbic acid or glutathione.

As the (2) lipophilic antioxidant, mention may be made of phenolic antioxidants which have a hindered phenol structure or a semi-hindered phenol structure within the molecule. As specific examples of such compounds, mention may be made of 3,5-bis(l,l-dimethylethyl)-4-hydroxybenzenepropanoic acid) which has the INCI name of pentaerythrityl tetra-di-t-butyl hydroxyhydrocinnamate, 2,6-di-tert-butyl-4-methylphenol, 2,6- di-tert-butyl-4-ethylphenol, 2-tert-butyl-4-methoxyphenol, 3-tert-butyl-4-methoxyphenol, mono- or di- or tri-(a-methylbenzyl)phenol, 2,2’-methylenebis(4-ethyl-6-tert-butylphenol), 2,2’-methylenebis(4-methyl-6-tert-butylphenol), 4,4’-butylidenebis(3-methyl-6-tert- butylphenol), 4,4’-thiobis(3-methyl-6-tert-butylphenol), 2,5-di-tert-butylhydroquinone, 2,5- di-tert-amylhydroquinone, tris[N-(3,5-di-tert-butyl-4-hydroxybenzyl)]isocyanurate, 1,1,3- tris(2-methyl-4-hydroxy-5-tert-butylphenyl)butane, butylidene- 1 , 1 bis [3 -(3 -tert-butyl -4- hydroxy-5-methylphenyl)propionate], octadecyl 3-(3,5-di-tert-butyl-4- hydroxyphenyl)propionate, tetrakis [methylene-3 -(3 ,5-di-tert-butyl-4- hydroxyphenyl)propionato]methane, triethylene glycol bis[3-(3-tert-butyl-4-hydroxy-5- methylphenyl)propionate] , 3 ,9-bis { 2- [3 -(3 -tert-butyl-4-hydroxy-5 - methylphenyl)propionyloxy]- 1 , 1 -dimethylethyl} -2,4,8, 10-tetraoxaspiro [5.5]undecane, 1,3,5- trimethyl-2,4,6-tris(3,5-di-tert-butyl-4-hydroxybenzyl)benzene, 2,2-thiodiethylenebis[3-(3,5- di-tert-butyl-4-hydroxyphenyl)propionate], N,N’-hexamethylenebis(3,5-di-tert-butyl-4- hydroxyhydrocinnamide), 1 ,6-hexanediol bis[3-(3,5-di-tert-butyl-4- hydroxyphenyl)propionate], l,3,5-tris[(4-tert-butyl-3-hydroxy-2,6-xylyl)methyl]-l,3,5- triazine-2, 4, 6-trione, 2,4-bis(n-octylthio)-6-(4-hydroxy-3,5-di-tert-butylanilino)-l,3,5-triazine, 2-tert-butyl-6-(3’-tert-butyl-5’-methyl-2’-hydroxybenzyl)-4-methylphenyl acrylate, 2-[l-(2- hydroxy-3,5-di-tert-pentylphenyl)ethyl]-4,6-di-tert-pentylphenyl acrylate, 4,6- bis [(octyl thio)methyl]-o-cresol, 2,4-di-tert-butylphenyl-3,5-di-tert-butyl-4-hydroxybenzoate and l,6-hexanediolbis[3-(3,5-di-tert-butyl-4-hydroxyphenyl) propionate].

As the (2) lipophilic antioxidant, mention may also be made of BHA (butylated hydroxyl anisole = 2-tert-butyl-4-methoxyphenol and/or 3-tert-butyl-4-methoxyphenol) and BHT (butylated hydroxyl toluene = di -tert-butyl 4-hydroxytoluene).

As the (2) lipophilic antioxidant, mention may also be made of vitamin E (or tocopherols and tocotrienol) and derivatives thereof, such as tocopheryl acetate.

As the (2) lipophilic antioxidant, mention may also be made of diphenyl acrylates, preferably alpha-cyanodiphenylacrylates which may be represented by the following general formula: wherein one or both of Ri and R2 is independently a straight or branched chain C1-30 alkoxy radical and any non-alkoxy Ri or R2 radical is hydrogen; and

R3 is a straight or branched chain C1-30 alkyl.

Alternately, one or both of Ri and R2 is independently a Ci-8 alkoxy radical and any non- alkoxy Ri or R2 radical is hydrogen; and R3 is a straight of branched chain C2-20 alkyl.

Alternately, one or both of Ri and R2 is independently methoxy, and any non-methoxy Ri or R2 is hydrogen; and R3 is a straight or branched chain C2-20 alkyl.

A suitable alpha-cyanodiphenylacrylate is ethylhexyl methoxycrylene, or 2-ethylhexyl 2- cyano-3-(4-methoxyphenyl)-3-phenylpropenoate, wherein Ri is methoxy, R2 is hydrogen, and R3 is 2-ethylhexyl.

As the (2) lipophilic antioxidant, mention may also be made of ferulic acid and derivatives thereof (esters, salts, etc.). Mention may particularly be made of esters of ferulic acid and of C1-C30 alcohols, in particular methyl ferulate, ethyl ferulate, isopropyl ferulate, and octyl ferulate, as well as oryzanol, in particular gamma-oryzanol, such as oryzanol-A, oryzanol-C and campesteryl ferulate.

As the (2) lipophilic antioxidant, mention may be made of non-phenolic antioxidants. For example, mention may be made of a sulfur-including non-phenolic compound including at least one sulfur atom, in particular thiodipropionic acid and derivatives thereof (esters, salts, etc.), such as dilauryl thiodipropionate, dimyristyl thiodipropionate and distearyl thiodipropionate.

It is preferable that the (2) lipophilic antioxidant be selected from the group consisting of dibutylhydroxytoluene (BHT), ethylhexyl methoxycrylene, tocopheryl acetate, oryzanol, pentaerythrityl tetra-di-t-butyl hydroxyhydrocinnamate, dilauryl thiopropionate, and mixtures thereof.

The amount of the (2) lipophilic antioxidant(s) in the composition according to the present invention may be 0.01% by weight or more, preferably 0.05% by weight or more, and more preferably 0.1% by weight or more, relative to the total weight of the composition.

On the other hand, the amount of the (2) lipophilic antioxidant(s) in the composition according to the present invention may be 10% by weight or less, preferably 5% by weight or less, and more preferably 3% by weight or less, relative to the total weight of the composition.

The amount of the (2) lipophilic antioxidant(s) in the composition according to the present invention may range from 0.01% to 10% by weight, preferably from 0.05% to 5% by weight, more preferably from 0.1% to 3% by weight, relative to the total weight of the composition.

The weight ratio of the amount of (1) thiopyridinone compound(s) to the amount of (2) lipophilic antioxidant(s), in the composition according to the present invention, may be 0.1 or more, preferably 0.4 or more, and more preferably 0.6 or more.

On the other hand, the weight ratio of the amount of (1) thiopyridinone compound(s) to the amount of (2) lipophilic antioxidant(s), in the composition according to the present invention, may be 4 or less, preferably 3 or less, and more preferably 2 or less. The weight ratio of the amount of (1) thiopyridinone compound(s) to the amount of (2) lipophilic antioxidant(s), in the composition according to the present invention, may range from 0.1 to 4, preferably from 0.4 to 3, and more preferably from 0.6 to 2.

(Combination of (2’))

According to one embodiment of the present invention, the composition according to the present invention may comprise a combination of (2’) (i) at least one selected antioxidant and (2’)(ii) at least one selected chelating agent.

The combination (2’) may further comprise (2’) (iii) at least one another antioxidant which is different from the (2’) (i) antioxidant.

The (2’) (i) antioxidant, the (2’) (ii) chelating agent, and the (2’) (iii) antioxidant are explained below.

(2’) (i) Antioxidant:

As the (2’) (i) antioxidant, a single antioxidant selected from cinnamic acid or a derivative thereof, hindered phenols or semi-hindered phenols, and thioester antioxidant may be used. Two or more antioxidants selected from cinnamic acid or a derivative thereof, hindered phenols or semi-hindered phenols, and thioester antioxidant may be used in combination.

The (2’) (i) antioxidant may be cinnamic acid or a derivative thereof, e.g., a phenylpropanoid. Phenylpropanoids include: cinnamic acid, caffeic acid, ferulic acid, trans-ferulic acid (including its antioxidant pharmacore 2,6-dihydroxy acetophenome), 5-hydroxyferic acid, sinapic acid, Coumarin, coniferyl alcohol, sinapyl alcohol, eugenol, Chavicol, baicalein, P- coumaric acid and sinapinic acid. Without limiting the mode of action of the present invention, phenylpropanoids can neutralize free radicals.

Amongst others, useful cinnamic acid derivatives may comprise 2-ethylhexyl methoxycinnamate, isopropyl methoxycinnamate, isoamyl methoxycinnamate, diisopropyl methoxycinnamate, pentaerythrityl tetra-di-t-butyl hydroxyhydrocinnamate (Tinogard TT), octadecyl di-t-butyl-4-hydroxyhydrocinnamate, caffeic acid, ferulic acid. Caffeic acid and ferulic acid may be preferable, and ferulic acid may be more preferable.

On the other hand, hindered phenols or semi-hindered phenols may be used as the (2’) (i) antioxidant(s) according to the present invention. Useful hindered phenols or semi-hindered phenols may comprise: mono- or di- or tri-(a-methylbenzyl)phenol, pentaerythrityl tetra-di-t- butyl hydroxyhydrocinnamate (Tinogard TT), 2,6-di-tert-butyl-4-methylphenol, 2.6-di-tert- butyl-4-ethylphenol, 4,4’-butylidenebis(3-methyl-6-tert-butylphenol) 2,2,-methylenebis(4- ethyl-.6-tert-butylphenol), 2,2’-methylenebis(4-methyl-6-tert- butylphenol), and benzotriazolyl dodecyl p-cresol.

Amongst others, pentaerythrityl tetra-di-t-butyl hydroxyhydrocinnamate is both a derivative of cinnamic acid and a hindered phenol, and is particularly preferred.

Another category of useful antioxidant is a thioester antioxidant, especially a polyester of thiodiacid or thiopolyacid, e.g., dilauryl thiodipropionate. According to the present invention, the (2’) (i) antioxidant(s) can be present in the composition from 0.1% to 2% by weight, preferably 0.1% to 1% by weight, more preferably 0.1% to 0.5% by weight, relative to the total weight of the composition according to the present invention.

(2’) (ii) Chelating Agent:

As the (2’) (ii) chelating agent, a single chelating agent selected from the group consisting of succinic acid and derivatives thereof, phosphor-containing organic acid and derivatives thereof may be used. Two or more chelating agent selected from the group consisting of succinic acid and derivatives thereof, phosphor-containing organic acid and derivatives thereof may be used in combination.

Such chelating agents are defined and described in particular in the article "Chelating agents" Kirk Othmer Encyclopedia of Chemical Technology, Vol. 5 pp. 708-739, published in 2003.

For the purpose of the present invention, useful chelating agents can comprise succinic acid and derivatives thereof, e.g., ethylenediamine disuccinic acid (EDDS), and a salt thereof; phosphor-containing organic acid, e.g., phytic acid, and a salt thereof, e.g., sodium phytate, potassium phytate.

These agents are particularly useful for reducing the electrostatic bonding associated with substantial presence of water in the intermediate makeup and/or care composition according to the invention. For example, a useful chelating agent is selected from the group consisting of trisodium EDDS, sodium phytate, potassium phytate, and mixtures thereof.

According to the present invention, the (2’) (ii) chelating agent can be present in the composition according to the present invention from 0.001% to 1% by weight, preferably from 0.01% to 0.5% by weight, relative to the total weight of the composition.

(2’) (iii) Antioxidant:

The (2’) combination used in the composition of the present invention may further comprise (2’) (iii) at least one antioxidant selected from the group consisting of tetrahexyl decyl ascorbate/erythorbate and ascorbyl palmitate, ascorbyl dipalmitate, ascorbyl tetraisopalmitate, magnesium ascorbyl phosphate, ascorbyl glucoside, glucosamine ascorbate, ascorbyl acetate, and tris(tetramethylhydroxypiperidinol) citrate.

As the additional (2’) (iii) antioxidant, oil soluble vitamin C derivatives can be used. The fat-soluble ester could be tetrahexyl decyl ascorbate/erythorbate and ascorbyl palmitate, ascorbyl dipalmitate, ascorbyl tetraisopalmitate, magnesium ascorbyl phosphate, ascorbyl glucoside, glucosamine ascorbate, ascorbyl acetate, and the like.

Besides the conventional antioxidants, some specific substances acting as an excited state quencher may also be used, and can be deemed as an “antioxidant” specifically for the purpose of the present invention. Without being limited with any known theory, it is believed that they can block the excited state to pull back to the ground state so that they can efficiently prevent the excited reaction and stabilize photodegradation. Except for the structure of citrate acid, there are also some hydroxyl groups. In the present invention, tris(tetramethylhydroxypiperidinol) citrate may be used. According to an embodiment of the present invention, the (2’) (iii) antioxidant can be present in the composition from 0% to 2% by weight, preferably 0.1% to 1% by weight, more preferably 0.1% to 0.5% by weight, relative to the total weight of the composition according to the present invention.

(pH Adjusting Agent)

The composition according to the present invention may comprise (3) at least one pH adjusting agent (pH adjuster). Two or more pH adjusting agents may be used in combination. Thus, a single type of pH adjusting agent or a combination of different types of pH adjusting agents may be used.

As the (3) pH adjusting agent, at least one acidifying agent and/or at least one basifying agent (alkaline agent) may be used.

The acidifying agent may be a monovalent or polyvalent, such as divalent, acid.

The acidifying agents can be, for example, mineral (inorganic) acids such as hydrochloric acid, sulfuric acid, phosphoric acid, or organic acids such as carboxylic acids, for instance tartaric acid, citric acid, and lactic acid, as well as sulphonic acids.

The basifying agent may be a monovalent or polyvalent, such as divalent, base.

The basifying agents may be mineral (inorganic) or organic, or hybrid.

The mineral basifying agents may be chosen from aqueous ammonia; alkali metal carbonates or bicarbonates such as sodium or potassium carbonates and sodium or potassium bicarbonates; alkali metal hydroxides such as sodium hydroxide and potassium hydroxide; and mixtures thereof.

The organic basifying agents may be chosen from organic amines with a pKb at 25°C of less than 12, preferably less than 10, and even more advantageously less than 6. It should be noted that it is the pKb corresponding to the function of highest basicity. In addition, the organic amines do not comprise any alkyl or alkenyl fatty chains comprising more than ten carbon atoms.

The organic basifying agent may be chosen, for example, from alkanolamines, oxyethylenated and/or oxypropyl enated ethylenediamines, amino acids and amine compounds of formula (III) below: in which W represents a Ci-Cg divalent alkylene radical optionally substituted with one or more hydroxyl groups or a Ci-Ce alkyl radical, and optionally interrupted with one or more heteroatoms such as O and N, and

R_x, R_y, R_z, and Rt, which may be identical or different, represent a hydrogen atom or a Ci-Ce alkyl, Ci-C₆ hydroxyalkyl, or Ci-Ce aminoalkyl radical.

Examples of the amine compounds of formula (III) that may be mentioned include 1,3- diaminopropane, l,3-diamino-2-propanol, spermine and spermidine.

The term “alkanolamine” means an organic amine comprising a primary, secondary or tertiary amine function, and one or more linear or branched Ci-C« alkyl groups bearing one or more hydroxyl radicals.

Alkanolamines such as monoalkanolamines, dialkanolamines or trialkanolamines comprising one to three identical or different C1-C4 hydroxyalkyl radicals may be suitable for the present invention. Among the compounds of this type, mention may be made of monoethanolamine (MEA), diethanolamine, triethanolamine, monoisopropanolamine, diisopropanolamine, N- dimethylaminoethanolamine, 2-amino-2-methyl-l -propanol, triisopropanolamine, 2-amino-2- methyl-l,3-propanediol, 3-amino-l,2-propanediol, 3-dimethylamino-l,2-propanediol and tris(hydroxymethylamino)methane.

Amino acids that may be used are of natural or synthetic origin, in their L, D or racemic form, and comprise at least one acid function chosen more particularly from carboxylic acid, sulfonic acid, phosphonic acid or phosphoric acid functions. The amino acids may be in neutral or ionic form.

As amino acids that may be used in the present invention, mention may be made especially of aspartic acid, glutamic acid, alanine, arginine, ornithine, citrulline, asparagine, carnitine, cysteine, glutamine, glycine, histidine, lysine, isoleucine, leucine, methionine, N- phenylalanine, proline, serine, taurine, threonine, tryptophan, tyrosine and valine.

It may be preferable that the amino acids are basic amino acids comprising an additional amine function optionally included in a ring or in an ureido function.

Such basic amino acids may preferably be chosen from those corresponding to formula (IV) below: in which

R represents a group chosen from:

-(CH₂)₃-NH₂,

-(CH₂)₂-NH₂, -(CH₂)2-NH-CO-NH₂, and

The compounds corresponding to formula (IV) include histidine, lysine, arginine, ornithine and citrulline.

The organic basifying agent may be chosen from organic amines of heterocyclic type. Besides histidine that has already been mentioned in the amino acids, mention may in particular be made of pyridine, piperidine, imidazole, triazole, tetrazole and benzimidazole.

The organic basifying agent may also be chosen from amino acid dipeptides. As amino acid dipeptides that may be used in the present invention, mention may be made especially of carnosine, anserine and baleine.

The organic basifying agent may also be chosen from compounds comprising a guanidine function. As amines of this type that may be used in the present invention, besides arginine, which has already been mentioned as an amino acid, mention may be made especially of creatine, creatinine, 1,1 -dimethylguanidine, 1,1-diethyl-guanidine, glycocyamine, metformin, agmatine, N-amidinoalanine, 3-guanidino-propionic acid, 4-guanidinobutyric acid and 2- ([amino(imino)methyl]amino)ethane- 1 -sulfonic acid.

In a preferred embodiment of the present invention, the organic basifying agent may be selected from amino acids, preferably basic amino acids, and more preferably arginine, lysine, histidine or mixtures thereof. Even more preferentially, the organic basifying agent may be arginine.

Hybrid compounds that may be mentioned include the salts of the amines mentioned previously with acids such as carbonic acid or hydrochloric acid. Guanidine carbonate or monoethanolamine hydrochloride may be used in particular.

The (3) pH adjusting agent may be present in an amount of 0.01% by weight or more, preferably 0.05% by weight or more, and more preferably 0.1% by weight or more, relative to the total weight of the composition.

The (3) pH adjusting agent may be present in an amount of 15% by weight or less, preferably 10% by weight or less, and more preferably 5% by weight or less, relative to the total weight of the composition.

The (3) pH adjusting agent may be present in an amount ranging from 0.01% to 15% by weight, preferably from 0.05% to 10% by weight, and more preferably from 0.1% to 5% by weight or less, relative to the total weight of the composition.

It is preferable that the composition according to the present invention have a pH of 4.5 or more, and more preferably 5 or more.

It is preferable that the composition according to the present invention have a pH of 6.5 or less, and more preferably 6 or less. It is preferable that the composition according to the present invention have a pH of from 4.5 to 6.5, and more preferably from 5 to 6.

The pH of the composition means the pH of the aqueous phase of the composition according to the present invention. The pH can be measured in accordance with JIS Z 8802 (2011).

It may be preferable that at least one buffer or buffering agent also be used, as the (3) pH adjusting agent, in combination with the acidifying agent and/or the basifying agent, in order to stabilize the pH of the composition according to the present invention.

As the buffer, any of commonly known buffers may be used. For example, salts of acids or bases, preferably salts of weak acids or weak bases, may be used. For example, sodium citrate or sodium lactate may be used as the buffer, if citric acid or lactic acid is used as the acidifying agent.

(Water)

The composition according to the present invention may comprise (4) water.

The amount of the (4) water in the composition according to the present invention may be 30% by weight or more, preferably 35% by weight or more, and more preferably 40% by weight or more, relative to the total weight of the composition.

On the other hand, the amount of the (4) water in the composition according to the present invention may be 99% by weight or less, preferably 95% by weight or less, and more preferably 90% by weight or less, relative to the total weight of the composition.

The amount of (4) water in the composition according to the present invention may be from 30% to 99% by weight, preferably from 35% to 95% by weight, and more preferably from 40% to 90% by weight, relative to the total weight of the composition.

(Other Optional Additives)

The composition according to the present invention may also comprise any other optional additive(s) usually used in the field of cosmetics, chosen, for example, from solvents, surfactants, cosmetic active agents other than ingredient (1), such as oils, preservatives, and mixtures thereof.

If the composition according to the present invention comprises the (2) lipophilic antioxidant and does not comprise the (2’) combination, it may also comprise at least one chelating agent.

It is a matter of routine operations for a person skilled in the art to adjust the nature and amount of the above optional additives which may be present in the composition in accordance with the present invention such that the desired cosmetic properties are not thereby affected.

As the solvents, mention may be made of one or several cosmetically acceptable organic solvents, which may be alcohols: in particular monovalent alcohols such as ethyl alcohol, isopropyl alcohol, benzyl alcohol, and phenylethyl alcohol; diols such as ethylene glycol, propylene glycol, and butylene glycol; other polyols such as glycerol, sugar, and sugar alcohols; and ethers such as ethylene glycol monomethyl, monoethyl, and monobutyl ethers, propylene glycol monomethyl, monoethyl, and monobutyl ether, and butylene glycol monomethyl, monoethyl, and monobutyl ethers.

The organic solvent(s) may be present in a concentration of from 0.01% to 30% by weight, preferably from 0.1% to 20% by weight, and more preferably from 1% to 10% by weight, relative to the total weight of the composition.

As the surfactants, mention may be made of a nonionic surfactant or a mixture thereof. Examples of the useful nonionic surfactants may comprise esters of polyols and of fatty acids with a saturated or unsaturated chain containing, and the oxyalkylenated derivatives thereof, i.e. derivatives containing oxyethylenated and/or oxypropylenated units, such as the glyceryl esters, and the oxyalkylenated derivatives thereof; the polyethylene glycol esters, and the oxyalkylenated derivatives thereof; the sorbitol esters, and the oxyalkylenated derivatives thereof; the sugar (sucrose, glucose or alkylglucose) esters, and the oxyalkylenated derivatives thereof; fatty alcohol ethers; the sugar ethers, and mixtures thereof.

Glyceryl esters of fatty acids that may especially be mentioned include glyceryl stearate (glyceryl monostearate, distearate and/or tristearate).

Polyethylene glycol esters of fatty acids that may especially be mentioned include polyethylene glycol 40 OE monostearate (CTFA name: PEG-40 stearate).

Mixtures of these surfactants may also be used.

The nonionic surfactant may be present in the composition according to the present invention in an amount from 0.1% to 15% by weight, such as from 0.15% to 10% by weight, relative to the total weight of the composition.

[Preparation]

The composition according to the present invention can be prepared by mixing the abovedescribed essential and optional ingredients in a conventional manner.

For example, the composition according to the present invention can be prepared by a process comprising the steps of mixing

(1) at least one thiopyridinone compound; and

(2) at least one lipophilic antioxidant; or

(2’) a combination of:

It is possible to further mix any of the optional ingredients. The mixing can be performed at any temperature such as room temperature (e.g., 20-25°C, preferably at 25°C), preferably at a temperature of 30°C or more, preferably 40°C or more, and more preferably 50°C or more. It is preferable to further mix with any of the abovedescribed optional ingredients such as a pH adjusting agent.

The form of the composition according to the present invention is not particularly limited, and may take various forms such as a W/O emulsion, an O/W emulsion, a gel, a solution, or the like. It is preferable that the composition according to the present invention be in the form of an emulsion, preferably an O/W emulsion, and more preferably an O/W gel emulsion. In a preferred embodiment according to the invention, the composition comprises hydrophilic gelling agents.

[Cosmetic Process]

The composition according to the present invention may be used as a cosmetic or dermatologic composition, preferably a cosmetic composition, and more preferably a cosmetic composition for a keratin substance. As the keratin substance, mention may be made of the skin, scalp, hair, mucosa such as lips, and nails.

The composition according to the present invention may be used as a depigmenting, bleaching or whitening product for a keratinous substance such as skin. In particular, the composition according to the present invention may be used as a whitening product.

The composition according to the present invention may preferably be intended for application onto a keratin substance such as the skin, scalp and/or the lips, preferably the skin.

Thus, the composition according to the present invention can be used for a cosmetic process for a keratin substance, preferably the skin. In one embodiment, the present invention relates to a cosmetic process, preferably a whitening process, for a keratin substance, preferably skin, comprising the step of applying onto the keratin substance the composition according to the present invention.

The composition according to the present invention can be used as a topical cosmetic composition in the form of a lotion, a milky lotion, a cream, a gel, a paste, a serum, foam, or spray.

The composition according to the present invention can also be used for a non-therapeutic cosmetic process for the care or makeup of keratin materials, comprising the application to the keratin materials of the composition according to the present invention.

[Use]

The present invention also relates to a use of:

(2) at least one lipophilic antioxidant; or

(2’) a combination of:

R2 denotes a radical chosen from a) a hydrogen atom, b) a saturated, linear C1-C12 or branched C3-C12 or cyclic C3-C8 hydrocarbonated group optionally substituted with one or more groups, which may be identical or different, chosen from i) -O-R3, ii) -S-R3, iii) -C(O)-O-R₃, and iv) a C5-C12 aryl group optionally substituted with one or more hydroxyls and/or with one or more Ci-Cs alkoxy radicals, and c) a C5-C12 aryl group optionally substituted with one or more hydroxyls and/or with one or more Ci-Cs alkoxy radicals, wherein

The term “stabilize” has the same meaning as enhancing stability.

The use according to the present invention can increase the stability of the (1) thiopyridinone compound in the composition comprising the same.

Therefore, the use according to the present invention can make it possible to store a composition comprising the (1) thiopyridinone compound for a long period of time, and in particular even under hot conditions. The above explanations regarding the (1) thiopyridinone compound and the (2) lipophilic antioxidant or the (2’) combination for the compositions according to the present invention can also apply to those used in the use according to the present invention.

The composition in the use according to the present invention may include any of the optional ingredients as explained above for the compositions according to the present invention.

More particularly, the subject of the invention is the cosmetic use of the composition according to the present invention, for the care of the skin, preferably for brightening the skin, and/or reducing or lightening darker and/or more coloured spots on the skin.

In a particular embodiment, the composition is suitable for the treatment of darker and/or more coloured spots on the skin.

[Particular Embodiments]

The present invention may be described by the following non-limiting embodiments:

1. A composition, preferably a cosmetic composition, comprising

(1) at least one compound selected from compounds of formula (I) below, tautomers of formula (I’) below, salts thereof, solvates, such as hydrates, thereof, optical isomers thereof, racemates thereof, and mixtures thereof:

(I) (I’) in which

(2) at least one lipophilic antioxidant. The composition according to embodiment 1 , wherein:

Ri of formula (I) and (I’) represents a hydrogen atom; or

Ri of formula (I) and (I’) represents a linear (C1-C10) alkyl group or a branched (C3- C10) alkyl group, especially a linear (Ci-Ce) alkyl group or a branched (C3-C6) alkyl group, such as methyl, ethyl, n-pentyl, n-nonyl, isobutyl, more preferably ethyl, particularly the said alkyl group of Riis not substituted. The composition according to embodiment 1 or 2, wherein:

R2 of formula (I) and (I’) represents a hydrogen atom; or

R2 of formula (I) and (I’) represents a linear (C1-C10) alkyl group or a branched (C3- C10) alkyl group, especially a linear (Ci-Ce) alkyl group or a branched (C3-C6) alkyl group, such as methyl, ethyl, n-pentyl, n-nonyl, isobutyl, more preferably methyl or ethyl group; the said alkyl group of R2 being not substituted. The composition according to embodiment 1 or 2, wherein:

R2 of formula (I) and (I’) represents a linear (C1-C10) alkyl group or a branched (C3- C10) alkyl group, especially a linear (C1-C6) alkyl group or a branched (C3-C6) alkyl group, such as methyl, ethyl, n-pentyl, n-nonyl, isobutyl, more preferably methyl or ethyl; the said alkyl group being substituted by one or more groups selected from i), ii), iii) and iv) as defined above, preferably the said alkyl group being substituted by one or two groups selected from i), ii) and iii), more preferably by one or two groups selected from i) and iii), better substituted by one group iii) as carboxy. The composition according to embodiment 1 or 2, wherein:

R2 of formula (I) and (T) represents a C5-C12 aryl group optionally substituted with one or more hydroxyls and/or with one or more Ci-Cs alkoxy radicals, preferably a phenyl group particularly not substituted. The composition according to any one of embodiments 1 to 5, wherein:

R3 of formula (I) and (I’) represents a hydrogen atom; or

R3 of formula (I) and (I’) represents a saturated, linear C1-C10 or branched C3-C10 alkyl group; particularly a linear (Ci-Ce) alkyl group or a branched (C3-C6) alkyl group, preferably a (C1-C4) alkyl group such as methyl group. The composition according to any one of embodiments 1 to 6, wherein:

Ri of formula (I) and (I’) represents a radical chosen from a) a hydrogen atom, and b) a saturated, linear Ci-Ce or branched C3-C6 alkyl group optionally substituted with one or more groups, which may be identical or different, chosen from i) -O-R3, and ii) -S-R3, preferably optionally substituted with one or more groups i);

R2 of formula (I) and (T) represents a radical chosen from a) a hydrogen atom, and b) a saturated, linear C1-C10 or branched C3-C10 or cyclic C3-C8 such as C5-

Ce hydrocarbonated group, optionally substituted with one or more groups, which may be identical or different, chosen from i) -O-R3, ii) -S-R3, iii) -C(O)-O-R₃, and iv) a phenyl group optionally substituted with one or more hydroxyls and/or with one or more C1-C4 alkoxy radicals such as methoxy, preferably substituted with one or more groups selected from i) and iii), preferably iii) such as carboxy; and

Ri of formula (I) and (I’) represents a radical chosen from: a) a hydrogen atom, and b) a saturated, linear C1-C4 or branched C3-C4 alkyl group optionally substituted with one or more groups, which may be identical or different, chosen from i) -OR3, more preferably not substituted;

R2 of formula (I) and (T) represents a radical chosen from a) a hydrogen atom, and b) a saturated, linear C1-C10 or branched C3-C10 or cyclic C3-C8 such as C5- Ce hydrocarbonated group, optionally substituted with one or more groups, which may be identical or different, chosen from i) -O-R3, iii) -C(O)-O-R₃, and iv) a C5-C12 aryl group optionally substituted with one or more hydroxyls and/or with one or more C1-C4 alkoxy radicals; and

R3 of formula (I) and (T) represents a radical chosen from: a) a hydrogen atom; b) a saturated, linear C1-C4 or branched C3-C4 alkyl group such as methyl or ethyl. The composition according to any one of embodiments 1 to 7, wherein: the (1) compound is selected from the compounds 1 to 24 below, tautomers thereof, salts thereof, solvates, such as hydrates, thereof, optical isomers thereof, racemates thereof, and mixtures thereof, particularly the compounds 1, 2, 4, 6, 7, 9, 11, 12, 14, 15, 16, 17, 18, 19, 20, or 21, more particularly 1, 9, 16, 18, 19, 20, or 21, preferably 18, 19, 20, or 21, and more preferably 20:

SUBSTITUTE SHEET(RULE2fi)

41

SUBSTITUTE SHEET(RUM . The composition according to any one of embodiments 1 to 8, wherein the amount of the (1) compound(s) in the composition is from 0.01% to 10% by weight, preferably from 0.05% to 5% by weight, and more preferably from 0.1% to 3% by weight, relative to the total weight of the composition.

10. The composition according to any one of embodiments 1 to 9, wherein the (2) lipophilic antioxidant is selected from the group consisting of dibutylhydroxytoluene, ethylhexyl methoxycrylene, tocopheryl acetate, oryzanol, pentaerythrityl tetra-di-t- butyl hydroxyhydrocinnamate, dilauryl thiopropionate, and mixtures thereof.

11. The composition according to any one of embodiments 1 to 10, wherein the amount of the (2) lipophilic antioxidant(s) in the composition is from 0.01% to 10% by weight, preferably from 0.05% to 5% by weight, more preferably from 0.1% to 3% by weight, relative to the total weight of the composition.

12. The composition according to any one of embodiments 1 to 11, wherein the composition is for whitening a keratin substance, preferably skin.

13. A cosmetic process, preferably a whitening process, for a keratin substance, preferably skin, comprising the step of: applying to the keratin substance the composition according to any one of embodiment 1 to 12.

14. Use of (2) at least one lipophilic antioxidant in a composition comprising (1) at least one compound selected from compounds of formula (I) below, tautomers of formula (F) below, salts thereof, solvates, such as hydrates, thereof, optical isomers thereof, racemates thereof, and mixtures thereof: in which

The present invention may be further described by the following non-limiting embodiments:

1. A composition comprising the components of:

A) at least one compound selected from compounds of formula (I) and tautomer of formula (I’) herein below; and their salts, optical isomers, racemates, and/or solvates such as hydrates, alone or as a mixture: in which Formulas (I) and (I’):

- Ri denotes a radical chosen from: a) a hydrogen atom; b) a saturated linear C1-C10 or branched C3-C10 alkyl group optionally substituted with one or more groups, which may be identical or different, chosen from: i) -0-R3 ii) -S-R₃;

- R2 denotes a radical chosen from: a) a hydrogen atom; b) a saturated hydrocarbonated group linear C1-C12 or branched C3-C12 or cyclic C3-C8, optionally substituted with one or more groups, which may be identical or different, chosen from: i) -O-R3 ii) -S-R3 iii) -C(O)-O-R₃; iv) a C5-C12 aryl group optionally substituted with one or more hydroxyls and/or with one or more Ci-Cs alkoxy radicals; c) a C5-C12 aryl group optionally substituted with one or more hydroxyls and/or with one or more Ci-Cs alkoxy radicals

- R3 denotes a radical chosen from: a) a hydrogen atom; b) a saturated linear C1-C10 or branched C3-C10 alkyl group;

B) at least one antioxidant selected from cinnamic acid or a derivative thereof, hindered phenols or semi-hindered phenols, and thioester antioxidant; e.g., pentaerythrityl tetra-di-t-butyl hydroxyhydrocinnamate, tris(tetramethylhydroxypiperidinol) citrate; and

C) at least one chelating agent selected from the group consisting of succinic acid and derivatives thereof, phosphor-containing organic acid and derivatives thereof. The composition according to embodiment 1, wherein:

- Ri of formula (I) and (I’) represents a hydrogen atom, or

- Ri of formula (I) and (I’) represents a linear (Ci-Cio)alkyl group or branched (C3- Cio)alkyl group, especially a linear (Ci-C6)alkyl group or branched (C3-Ce)alkyl group, such as methyl, ethyl, n-pentyl, n-nonyl, isobutyl, more preferably ethyl, particularly the said alkyl group of Ri is not substituted.

The composition according to any one of the preceding embodiments, wherein:

- R2 of formula (I) and (I’) represents a hydrogen atom; or

- R2 of formula (I) and (I’) represents a linear (Ci-Cio)alkyl group or branched (C3- Cio)alkyl group, especially a linear (Ci-Ce)alkyl group or branched (C3-Ce)alkyl group, such as methyl, ethyl, n-pentyl, n-nonyl, isobutyl, more preferably methyl or ethyl group; the said alkyl group of R2 being not substituted.

4. The composition according to embodiment 1 or 2, wherein:

- R2 of formula (I) and (T) represents a linear (Ci-Cio)alkyl group or branched (C3- Cio)alkyl group, especially a linear (Ci-C6)alkyl group or branched (C3-Ce)alkyl group, such as methyl, ethyl, n-pentyl, n-nonyl, isobutyl, more preferably methyl or ethyl; the said alkyl group being substituted by one or more groups selected from i), ii), iii) and iv) as defined in embodiment 1 , preferably the said alkyl group being substituted by one or two groups selected from i), ii) and iii), more preferably by one or two groups selected from i) and iii), better substituted by one group iii) as carboxy.

5. The composition according to embodiment 1 or 2, wherein

- R2 of formula (I) and (I’) represents a (C3-Cs)cycloalkyl group, preferably a (C5- C?)cycloalkyl group such cyclohexyl; or

- R2 of formula (I) and (I’) represents a C5-C12 aryl group optionally substituted with one or more hydroxyls and/or with one or more Ci-Cs alkoxy radicals, preferably a phenyl group particularly not substituted.

6. The composition according to any one of the preceding embodiments, wherein

- R3 of formula (I) and (I’) represents a hydrogen atom; or

- R3 of formula (I) and (T) represents a saturated linear C1-C10 or branched C3-C10 alkyl group; particularly a linear (Ci-C6)alkyl group or a branched (C3-Ce)alkyl group, preferably (Ci-C4)alkyl group such as methyl group.

7. The composition according to any one of the preceding embodiments, wherein:

- Ri of formula (I) and (I’) represents a radical chosen from: a) a hydrogen atom; b) a saturated linear Ci-Ce or branched C3-C6 alkyl group optionally substituted with one or more groups, which may be identical or different, chosen from: i) -O-R3 ii) -S-R3; preferably optionally substituted with one or more groups i)

- R2 of formula (I) and (T) represents a radical chosen from: a) a hydrogen atom; b) a saturated hydrocarbonated group linear C1-C10 or branched C3-C10 or cyclic C3-C8 such as C5-C6, optionally substituted with one or more groups, which may be identical or different, chosen from: i) -O-R3 ii) -SR-3 iii) -C(O)-O-R₃; iv) a phenyl group optionally substituted with one or more hydroxyls and/or with one or more C1-C4 alkoxy radicals such as methoxy; preferably substituted with one or more groups selected from i) and iii), preferably iii) such as carboxy - R3 of formula (I) and (I’) represents a radical chosen from: a) a hydrogen atom; b) a saturated linear Ci-Cg or branched C3-C6 alkyl group; preferentially, the compounds of formula (I) and tautomer (I’) or their salts, their optical isomers, racemates, and/or solvates such as hydrates and the thereof, alone or as a mixture have the following meanings:

- Ri of formula (I) and (I’) represents a radical chosen from: a) a hydrogen atom; b) a saturated linear C1-C4 or branched C3-C4 alkyl group optionally substituted with one or more groups, which may be identical or different, chosen from i) -OR3 , more preferably not substituted;

- R2 of formula (I) and (I’) represents a radical chosen from: a) a hydrogen atom; b) a saturated hydrocarbonated group linear Ci-Cio or branched C3-C10 or cyclic C3-C8 as C5-C6, optionally substituted with one or more groups, which may be identical or different, chosen from: i) -O-R3 iii) -C(O)-O-R₃; iv) a C5-C12 aryl group optionally substituted with one or more hydroxyls and/or with one or more C1-C4 alkoxy radicals;

- Rj of formula (I) and (I’) represents a radical chosen from: a) a hydrogen atom; b) a saturated linear C1-C4 or branched C3-C4 alkyl group such as methyl or ethyl. . The composition according to any one of the preceding embodiments, wherein the compound of formula (I) selected out from the group consisting of the compounds 1 to 24 below and their tautomer or their salts, their optical isomers, racemates, and/or solvates such as hydrates, alone or as a mixture, particularly compounds 1, 2, 4, 6, 7, 9, 11 , 12, 14, 15, 16, 17, 18, 19, 20, or 21, more particularly 1, 9, 16, 18, 19, 20, or 21, preferably 18, 19, 20, or 21, more preferably 20:

47

SUBSTITUTE SHEETfRUIM . The composition according to any one of the preceding embodiments, wherein the compound of formula (I) or (I’) is present in an amount ranging from 0.01% to 10% by weight, preferably from 0.1% to 5% by weight, or preferably from 0.5% to 3% by weight, relative to the total weight of the composition.

10. The composition according to any one of the preceding embodiments, wherein the component B) further comprises an antioxidant 2 selected from the group consisting of tetrahexyl decyl ascorbate/erythorbate and ascorbyl palmitate, ascorbyl dipalmitate, ascorbyl tetraisopalmitate, magnesium ascorbyl phosphate, ascorbyl glucoside, glucosamine ascorbate, ascorbyl acetate, and tris(tetramethylhydroxypiperidinol) citrate.

11. The composition according to any one of the preceding embodiments, wherein the antioxidant 1 is present in the composition from 0.1 % to 2 % by weight, preferably 0.1 % tol% by weight, more preferably 0.1% to 0.5 % by weight, relative to the total weight of the composition according to the present invention; and/or the antioxidant 2 is present in the composition from 0% to 2% by weight, preferably 0.1% to 1% by weight, more preferably 0.1% to 0.5 % by weight, relative to the total weight of the composition.

12. The composition according to anyone of the preceding embodiments, wherein the chelating agent is selected from ethylenediamine disuccinic acid (EDDS), and a salt thereof; phosphor-containing organic acid, e.g., phytic acid, and a salt thereof, e.g., sodium phytate, potassium phytate.

13. The composition according to anyone of the preceding embodiments, wherein the chelating agent is present in the second composition from 0.001% to 1% by weight, preferably from 0.01% to 0.5% by weight, relative to the total weight of the composition.

14. Use of the combination of component B) an antioxidant comprising antioxidant 1 selected from cinnamic acid or a derivative thereof, and hindered phenols or semi-hindered phenols, e.g., pentaerythrityl tetra-di-t-butyl hydroxyhydrocinnamate; and component C) at least one chelating agent selected from the group consisting of sodium citrate, disodium EDTA, tetrasodium EDTA, tetrasodium GLDA, trisodium EDDS, sodium phytate, potassium phytate, and mixtures thereof, for stabilizing the compound of formula (I) and tautomer of formula (I’) as defined in any one of embodiments 1 to 8, e.g., for stabilizing the compound 20.

15. A non-therapeutic cosmetic process for depigmenting, lightening and/or bleaching keratin materials, preferably skin, comprising the step of: applying to the keratin substance the composition according to any one of embodiments 1 to 13.

EXAMPLES

The present invention will be described in a more detailed manner by way of examples. However, these examples should not be construed as limiting the scope of the present invention.

[Examples 1A-6A and Comparative Example 1A]

[Preparation]

Each of the compositions according to Examples 1A-6A and Comparative Example 1A was prepared by mixing the ingredients shown in Table 1. The numerical values for the amounts of the ingredients are all based on “% by weight” as active materials.

Table 1

N-[(2-thioxo-l,2-dihydropyridin-3-yl)carbonyl]glycine (2-MERCAPTONICOTINOYL GLYCINE): Compound 20

[Evaluations]

(Thiopyridinone Compound Remaining Rate)

The amount of the thiopyridinone compound in each of the compositions according to Examples 1 A-6A and Comparative Example 1 A was measured by an HPLC-UV assay at the following timing.

Timing (1) Just after the preparation of the composition (TO)

Timing (2) 2 weeks after the preparation, where the composition was maintained in a sealed and light-shielding container at 55°C

The details of the HPLC-UV assay are as follows.

Apparatus/Reagents

The thiopyridinone compound remaining rate was determined by the following equation:

Thiopyridinone Compound Remaining Rate (%) =

Amount of Thiopyridinone Compound at Timing (2)/ Amount of Thiopyridinone Compound at Timing (1)

The results are shown in the “Thiopyridinone Compound Remaining Rate (%)” line in Table 2 below.

The thiopyridinone compound remaining rate was also categorized in accordance with the following criteria:

Very Good: 90% or more

Good: more than 85% to less than 90%

Poor: 85% or less The results are shown in the “Stability” line in Table 2 below.

Table 2

(Results)

The compositions according to Examples 1 A-6A, each of which included a thiopyridinone compound and a variety of lipophilic antioxidants, were more stable, even under elevated temperature, such that a greater amount of the thiopyridinone compound remained, than the composition according to Comparative Example 1 A which did not include any lipophilic antioxidant.

[Examples 1B-6B and Comparative Examples 1B-4B]

The compounds are indicated in chemical name or INCI name. The ingredient amounts/concentrations in the compositions/formulas described below are expressed in % by Compound 20 is synthesized as disclosed in example 2 of patent EP3390363.

[Preparation]

The inventive compositions of Ex.lB-Ex.6B, as well as comparative compositions of CE.1B- CE.4B, were prepared, from the ingredients indicated in the Tables 3-4 below (in which the contents were indicated in % by weight of materials with regard to the total weight of the composition):

Table 4

The compositions were prepared by the steps of, taking Ex. IB as an example:

1). Heating the surfactant, fatty compounds and antioxidants round 75°C, mixing well till all solid melted.

2). Mixing water, glycol, chelator and, if used, and heating to 75°C, mixing well till no lumps.

3). Transferring oil phase into water phase at 75°C, mixing homogenously for 15 mins.

4). Cooling to 30°C.

5). Finally adding Compound 20 and Sodium Hydroxide to adjust pH to be 5.7 + 0.3.

[Evaluations]

The inventive compositions of Ex.lB-Ex.6B, as well as comparative composition of CE.1B- CE.4B, prepared in the above “Preparation” section were evaluated for the degradation of COMPOUND 20, by the steps of:

- Exactly weighing 100 mg of the inventive and comparative compositions respectively into 10 mL volumetric flasks;

- Adding 2.5 mL of Ultra-pure water into it and tightening the cover, and then shaking it on vortex to make it well dispersed, no obvious agglomeration;

- Filling the methanol up to the line of the volumetric flask, and closing the lid tightly; Sonicating the solution 5 minutes and then cooling down to the room temperature; Stirring the solution on the magnetic stirring plate 1.5 hours; and

- Filtering the solution with 0.45 pGHP filter to get the injection solution; and subsequently: - First, doing UPLC (Ultra-performance liquid chromatography) analysis on the test compositions to get TO COMPOUND 20 degradation data; every composition having two parallel samples to be analyzed; where TO means the time of starting the degradation test;

Then putting the compositions into 45 °C oven for accelerating aging Test for 2 months; and

Finally, doing analysis on the aged compositions; every composition having two parallel samples to be analyzed. The results were given in Table 5 below.

Table 5

Claims

CLAIMS A composition, preferably a cosmetic composition, comprising

(1) at least one compound selected from compounds of formula (I) below, tautomers of formula (I’) below, salts thereof, solvates, such as hydrates, thereof, optical isomers thereof, racemates thereof, and mixtures thereof: in which

(2) at least one lipophilic antioxidant; or

(2’) a combination of:

(ii) at least one chelating agent selected from the group consisting of succinic acid and derivatives thereof, phosphor-containing organic acid and derivatives thereof. The composition according to Claim 1, wherein:

Ri of formula (I) and (T) represents a hydrogen atom; or

Ri of formula (I) and (!’) represents a linear (Ci-Cio) alkyl group or a branched (C3- C10) alkyl group, especially a linear (Ci-Ce) alkyl group or a branched (C3-C6) alkyl group, such as methyl, ethyl, n-pentyl, n-nonyl, isobutyl, more preferably ethyl, particularly the said alkyl group of Riis not substituted. The composition according to Claim 1 or 2, wherein:

R2 of formula (I) and (T) represents a hydrogen atom; or

R2 of formula (I) and (I’) represents a linear (C1-C10) alkyl group or a branched (C3- C10) alkyl group, especially a linear (Ci-Ce) alkyl group or a branched (C3-C6) alkyl group, such as methyl, ethyl, n-pentyl, n-nonyl, isobutyl, more preferably methyl or ethyl group; the said alkyl group of R2 being not substituted. The composition according to Claim 1 or 2, wherein:

R2 of formula (I) and (T) represents a linear (C1-C10) alkyl group or a branched (C3- C10) alkyl group, especially a linear (Ci-Ce) alkyl group or a branched (C3-C6) alkyl group, such as methyl, ethyl, n-pentyl, n-nonyl, isobutyl, more preferably methyl or ethyl; the said alkyl group being substituted by one or more groups selected from i), ii), iii) and iv) as defined above, preferably the said alkyl group being substituted by one or two groups selected from i), ii) and iii), more preferably by one or two groups selected from i) and iii), better substituted by one group iii) as carboxy. The composition according to Claim 1 or 2, wherein:

R2 of formula (I) and (I’) represents a C5-C12 aryl group optionally substituted with one or more hydroxyls and/or with one or more Ci-Cs alkoxy radicals, preferably a phenyl group particularly not substituted. The composition according to any one of Claims 1 to 5, wherein:

R3 of formula (I) and (T) represents a hydrogen atom; or

R3 of formula (I) and (I’) represents a saturated, linear C1-C10 or branched C3-C10 alkyl group; particularly a linear (Ci-Ce) alkyl group or a branched (C3-C6) alkyl group, preferably a (C1-C4) alkyl group such as methyl group. The composition according to any one of Claims 1 to 6, wherein: Ri of formula (I) and (I’) represents a radical chosen from a) a hydrogen atom, and b) a saturated, linear Ci-Ce or branched C3-C6 alkyl group optionally substituted with one or more groups, which may be identical or different, chosen from i) -O-R3, and ii) -S-R3, preferably optionally substituted with one or more groups i);

R.2 of formula (I) and (I’) represents a radical chosen from a) a hydrogen atom, and b) a saturated, linear C1-C10 or branched C3-C10 or cyclic C3-C8 such as C5- Ce hydrocarbonated group, optionally substituted with one or more groups, which may be identical or different, chosen from i) -O-R3, ii) -S-R3, iii) -C(O)-O-R₃, and iv) a phenyl group optionally substituted with one or more hydroxyls and/or with one or more C1-C4 alkoxy radicals such as methoxy, preferably substituted with one or more groups selected from i) and iii), preferably iii) such as carboxy; and

R2 of formula (I) and (I’) represents a radical chosen from a) a hydrogen atom, and b) a saturated, linear C1-C10 or branched C3-C10 or cyclic C3-C8 such as C5- Ce hydrocarbonated group, optionally substituted with one or more groups, which may be identical or different, chosen from i) -O-R3, iii) -C(O)-O-R₃, and iv) a C5-C12 aryl group optionally substituted with one or more hydroxyls and/or with one or more C1-C4 alkoxy radicals; and

8. The composition according to any one of Claims 1 to 7, wherein: the (1) compound is selected from the compounds 1 to 24 below, tautomers thereof, salts thereof, solvates, such as hydrates, thereof, optical isomers thereof, racemates thereof, and mixtures thereof, particularly the compounds 1, 2, 4, 6, 7, 9, 11, 12, 14, 15, 16, 17, 18, 19, 20, or 21, more particularly 1, 9, 16, 18, 19, 20, or 21, preferably 18, 19, 20, or 21, and more preferably 20:

SUBSTITUTE SHEET(RtW)

SUBSTITUTE SHEET(RUIBS)

SUBSTITUTE SHEETtRULE® The composition according to any one of Claims 1 to 8, wherein the amount of the (1) compound(s) in the composition is from 0.01% to 10% by weight, preferably from 0.05% to 5% by weight, and more preferably from 0.1% to 3% by weight, relative to the total weight of the composition. The composition according to any one of Claims 1 to 9, wherein: the (2) lipophilic antioxidant is selected from the group consisting of dibutylhydroxytoluene, ethylhexyl methoxycrylene, tocopheryl acetate, oryzanol, pentaerythrityl tetra-di-t-butyl hydroxyhydrocinnamate, dilauryl thiopropionate, and mixtures thereof. The composition according to any one of Claims 1 to 10, wherein: the amount of the (2) lipophilic antioxidant(s) in the composition is from 0.01% to 10% by weight, preferably from 0.05% to 5% by weight, more preferably from 0.1% to 3% by weight, relative to the total weight of the composition. The composition according to any one of Claims 1 to 11, wherein: the (2’) (ii) chelating agent is selected from ethylenediamine disuccinic acid (EDDS), and a salt thereof; phosphor-containing organic acid, e.g., phytic acid, and a salt thereof, e.g., sodium phytate, potassium phytate.

13. The composition according to any one of Claims 1 to 12, wherein: the (2’) combination further comprises (2’) (iii) at least one antioxidant selected from the group consisting of tetrahexyl decyl ascorbate/erythorbate and ascorbyl palmitate, ascorbyl dipalmitate, ascorbyl tetraisopalmitate, magnesium ascorbyl phosphate, ascorbyl glucoside, glucosamine ascorbate, ascorbyl acetate, and tris(tetramethylhydroxypiperidinol) citrate.

14. The composition according to any one of Claims 1 to 13, wherein: the amount of the (2’) (i) antioxidant(s) in the composition is from 0.1% to 2% by weight, preferably from 0.1% to 1% by weight, more preferably from 0.1% to 0.5% by weight, relative to the total weight of the composition; and/or the amount of the (2’) (ii) chelating agent(s) in the composition is from 0.001% to

1% by weight, preferably from 0.01% to 0.5% by weight, relative to the total weight of the composition; and/or the amount of the (2’) (iii) antioxidant(s) in the composition is from 0% to 2% by weight, preferably 0.1% to 1% by weight, more preferably 0.1% to 0.5% by weight, relative to the total weight of the composition.

15. Use of:

(2) at least one lipophilic antioxidant; or

(2’) a combination of:

(ii) at least one chelating agent selected from the group consisting of succinic acid and derivatives thereof, phosphor-containing organic acid and derivatives thereof, in a composition comprising (1) at least one compound selected from compounds of formula (I) below, tautomers of formula (T) below, salts thereof, solvates, such as hydrates, thereof, optical isomers thereof, racemates thereof, and mixtures thereof:

(I) (I’) in which

R.2 denotes a radical chosen from a) a hydrogen atom, b) a saturated, linear C1-C12 or branched C3-C12 or cyclic C3-C8 hydrocarbonated group optionally substituted with one or more groups, which may be identical or different, chosen from i) -O-R3, ii) -S-R3, iii) -C(O)-O-R3, and iv) a C5-C12 aryl group optionally substituted with one or more hydroxyls and/or with one or more Ci-Cs alkoxy radicals, and c) a C5-C12 aryl group optionally substituted with one or more hydroxyls and/or with one or more Ci-Cg alkoxy radicals, wherein